Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.
Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.
Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, Korea, South.
Jung Yong
JY
Hong
Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, Korea, South.
Cheolwon
C
Suh
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University, Seoul, 135-710, Korea, South.
Won Seog
WS
Kim